Alpha-Synuclein PMCA Detection for Early Parkinson's Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease lack sensitivity and objectivity in detecting misfolded alpha-synuclein protein, which is crucial for early detection before irreversible neuropathological changes occur.
Innovation Solution
The method involves Protein Misfolding Cyclic Amplification (PMCA) to amplify and detect misfolded alpha-synuclein protein by forming an incubation mixture with a molar excess of monomeric, folded alpha-synuclein protein, disrupting aggregates to release soluble misfolded alpha-synuclein, and using indicators like Thioflavin T for fluorescence detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for Parkinson's disease, then the diagnostic process is simple, but the sensitivity and objectivity of detecting misfolded alpha-synuclein protein are insufficient
Solution Approach 1:
The method performs preliminary amplification of misfolded alpha-synuclein protein through cyclic aggregation reactions before detection. By pre-concentrating the target protein using monomeric alpha-synuclein as bait and cyclic aggregation with sonication, the method enhances detection sensitivity before the actual measurement step, resolving the contradiction between simple diagnostics and high sensitivity detection
Solution Approach 2:
The invention introduces monomeric alpha-synuclein protein as an intermediary substance that binds to misfolded alpha-synuclein in the sample. This intermediary acts as a mediator that concentrates the target protein through repeated aggregation cycles, enabling sensitive detection without requiring complex direct detection apparatus
2Measurement precision
If misfolded alpha-synuclein protein is detected at low concentrations, then early diagnosis is enabled, but the detection limit of conventional methods is insufficient
Solution Approach 1:
The cyclic amplification process performs preliminary concentration of misfolded alpha-synuclein protein by repeatedly binding monomeric alpha-synuclein to misfolded forms and using sonication to release and re-bind. This pre-concentration step enables detection of extremely low concentrations of misfolded protein that would be below the detection limit of conventional methods
Solution Approach 2:
The method changes the physical state and concentration parameters of misfolded alpha-synuclein through cyclic aggregation and disruption. By repeatedly cycling between aggregation (increasing local concentration) and sonication disruption (releasing and redistributing), the method amplifies the effective concentration of misfolded protein for detection
3Measurement precision
If misfolded alpha-synuclein aggregates are disrupted to release soluble protein, then detection sensitivity is improved, but the process requires additional steps
Solution Approach 1:
The method employs periodic cyclic action combining aggregation incubation and sonication disruption steps. Each cycle consists of incubating monomeric alpha-synuclein with the sample followed by sonication, then repeating the process. This periodic cycling amplifies misfolded protein detection sensitivity while maintaining a standardized, efficient workflow that can be automated
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables ultra-sensitive detection of misfolded alpha-synuclein protein with high specificity and sensitivity, allowing for early diagnosis of Parkinson's disease and other disorders associated with alpha-synuclein misfolding.
Implementation Method 1
using indicators like Thioflavin T for fluorescence detection
Implementation Method 2
Each incubation cycle may include incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein
Implementation Method 3
Each incubation cycle may include physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present
Data Source
AI summary
Methods and kits are provided for amplifying and detecting αS proteins from samples, for example, from patients having Parkinson's Disease. For example, a method for determining a presence of a soluble, misfolded αS protein may include: contacting the sample with a monomeric, folded αS protein to form an incubation mixture; conducting an incubation cycle two or more times on the incubation mixture effective to form an amplified portion of misfolded αS protein; incubating the incubation mixture effective to cause misfolding and/or aggregation of at least a portion of the monomeric, folded αS protein in the presence of the soluble, misfolded αS protein; physically disrupting the incubation mixture effective to at least partly de-aggregate at least a portion of a misfolded αS aggregate present; and determining the presence of the soluble, misfolded αS protein in the sample by detecting at least a portion of the soluble, misfolded αS protein.